Editorial Team Conflict of Interest Statements
|
|
|
- Allen Merritt
- 5 years ago
- Views:
Transcription
1 Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies, Ethicon Johnson & Johnson, Zogenix, Supernus, Tonix, Labrys, Boston Scientific, St Jude, Bristol-Myers Squibb, MAP Honoraria: IntraMed, SAGE Publications, Sun Pharma, Allergan, Oxford University Press, Cambridge University Press, American Academy of Neurology, West Virginia University Foundation, Canadian Headache Society, American Headache Society, International Headache Society, Healthlogix, Wiley, Universal Meeting Management, WebMD, UptoDate, Haymarket Media Ltd, Oregon Health Science Center, Baylor University Medical Center, University of Miami Medical Center, System, Starr Clinical Decision Resources, University of British Columbia, and Synergy Associate Editors Frank Andrasik Honoraria: Editor-in-Chief, Applied Psychophysiology and Biofeedback Speaker: AHS CMEP program workshop Messoud Ashina Advisory board/consultant: ATI, Allergan, Amgen and Alder Biopharmaceuticals. Honoraria: Allergan. Principal investigator: Pathway M-1 trial (Autonomic Technologies, Inc.) and two ongoing phase III clinical trials (Amgen) David Borsook Consultant: Merck, Biogen and Electrocore
2 Rami Burstein Grants and/or honoraria: Allergan, GSK, Merck, Teva, Depomed, and Patent A combination therapy of statin and vitamin D for migraine prophylaxis, pending Andrew Charles Advisory board: Amgen, eneura and St. Jude Medical Grant: Takeda Pharmaceuticals Speaker: American Headache Society F Michael Cutrer Royalties: Up to Date as an author for several topics Hans-Christoph Diener Advisory board/consultant: Addex Pharma, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid, Böhringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Grünenthal, Janssen-Cilag, Lilly, La Roche, 3M Medica, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, SanofiAventis, Weber & Weber Grants: Allergan, Almirall, AstraZeneca, Bayer, GSK, Janssen-Cilag, Pfizer. Honoraria: clinical trials Headache research at the Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. Anne Ducros Consultant/speaker: Amgen/Bausch & Lomb
3 Lars Edvinsson Stefan Evers Advisory board/honoraria: Allergan; Eisai; Electrocore; GSK; Ipsen; Menarini; Merz; MSD; Mundipharma; Pfizer; Reckitt Benckiser; UCB Grants: Deutsche Forschungsgemeinschaft; Bundesministerium für Bildung und Forschung; Allergan. Salary: Verein zur Betreuung Schwerbehinderter e.v. (Lindenbrunn Hospital, Coppenbrügge, Germany). Michel Ferrari. Edith Hamel Andrew Hershey Board member: American Headache Society Consultant: Amgen and Allergan Editorial board: Cephalalgia, Headache, JHP Grant: NIH
4 Tobias Kurth Positions: Directeur de Recherche, Institut National de la Santé et de la Recherche Médicale (Inserm), Research Center for Epidemiology and Biostatistics and University of Bordeaux, Bordeaux, France. Adjunct Professor of Epidemiology, Harvard School of Public Health, Boston, MA. Adjunct epidemiologist, Division of Preventive Medicine, Brigham and Women s Hospital, Boston, MA. Member, Board of Trustees, International Headache Society. Relationship disclosure: Dr. Kurth has received investigator-initiated research funding from the French National Research Agency and the US National Institutes of Health. Further, he has received honoraria from the BMJ and Cephalalgia for editorial services and travel support from the International Headache Society. Elizabeth Loder Clinical editor: BMJ Arne May Consultant/speaker: Pfizer, Bayer Vital, GSK, Allergan, ATI, MSD, Electrocore, TEVA and Desitin. Editorial board: Cephalalgia, J Headache and Pain, European Neurology and Der Schmerz. Funded by the University Clinic of Hamburg. Scientific funds by the Deutsche Forschungsgemeinschaft (DFG) and the European Union s Research and Innovation funding Programme (FP7). Frank Porreca R Allan Purdy Advisory board: Tribute Pharmaceuticals makers of diclofenac potassium, and Electrocore (one meeting) Education grant: CME University Programs in Montreal and Quebec City by Allergan Canada. They had no part in the presentations and their product was not mentioned
5 Ann Scher Advisory board/consultant: Allergan Grant: Center from Neuroscience and Regenerative Medicine, Defense Medical Research and Development Program (DMRDP) Jean Schoenen Advisor: Allergan, Amgen, ElectroCore, and St Jude Medical Consultant: Cefaly Technology, Gedeon Richter Pharma, Chordate, ATI, and Medtronic Todd Schwedt Stephen Silberstein Advisory panel member and/ or consultant: Alder Biopharmaceuticals; Allergan, Inc.; Amgen; Avanir Pharmaceuticals, Inc.; Dr. Reddy s Laboratories; eneura Inc.; ElectroCore Medical, LLC; Medscape, LLC; Medtronic, Inc.; Mitsubishi Tanabe Pharma America, Inc.; NINDS; Supernus Pharmaceuticals, Inc. and Teva Pharmaceuticals. His employer receives research support from Allergan, Inc.; Amgen; Cumberland Pharmaceuticals, Inc.; ElectroCore Medical, LLC; Eli Lilly and Company; Merz Pharmaceuticals; and Teva Pharmaceuticals. Maurice Vincent Consultant: Allergan in chronic migraine
6 Shuu-jiun Wang Consultant: Allergan, Daiichi-Sankyo, Eli Lilly (Taiwan), Pfizer Speaker s Bureau: Allergan, MSD (Taiwan), Eli Lilly (Taiwan), GSK (Taiwan), Pfizer (Taiwan) Biostatics Editors Richard Chiacchierini Jayawant Mandrekar Book Reviews Editor Richard Peatfield Historical Section Editor Peter J Koehler
7 Ombudsman Peter J Goadsby Grants/ personal fees: Allergan, eneura, Amgen. Personal fees: Autonomic Technologies, Inc., BristolMyerSquibb, AlderBio, Pfizer, Impax, DrReddy, Zonsano, Colucid, Eli-Lillyl, Medtronic, Avanir, Gore, Journal Watch, Heptares, Nupathe, Teva. Personal fees: MedicoLegal in headache. Personal fees: Up-to-Date, outside the submitted work. Publishing and Scientific Integrity Advisor Robert Daroff Managing Editor Wendy Krank
Promius Pharma, a subsidiary of Dr. Reddy s Laboratories, Princeton, NJ; 2 Vedanta Research, Chapel Hill, NC; 3
Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study Aftab Alam, MBBS, MS, MBA 1 ; Sagar Munjal, MD 1
Joel R. Saper, 1 Richard B. Lipton, 2 David B. Kudrow, 3 Joe Hirman, 4 David W. Dodick, 5 Stephen Silberstein, 6 George Chakhava, 7 Jeff Smith 8
Primary Results of PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial: a Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and
Per cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT
Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological
Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
Stroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
ISSN doi: /head.13327
Headache VC 18 The Authors Headache: The Journal Head and Face Pain published by Wiley Periodicals, Inc. on behalf American Headache Society ISSN 17-8748 doi:.1111/head.13327 Research Submission Use Most
Triptans: Nonresponse, Recurrence, and Serious AEs for Many Patients
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
Richard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database
doi:10.1111/j.1468-2982.2007.01457.x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M
Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD
Differentiating Migraine from Other Headache Types to Target Treatment Peter J. Goadsby, MD, PhD University of California, San Francisco San Francisco, CA King's College London London, England Learning
Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan
J Headache Pain (2008) 9:359 365 DOI 10.1007/s10194-008-0070-6 ORIGINAL Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan Hans-Christoph
Disclosure. Learning Objectives 11/10/2017. The Best and Most Interesting Research from Last Year Cephalalgia
The Best and Most Interesting Research from Last Year Cephalalgia David W. Dodick, M.D. Department of Neurology Mayo Clinic Scottsdale Arizona Disclosure Consulting services: Acorda, Allergan, Amgen, Alder,
6/20/2018. Chronic Migraine versus Chronic Pain: Similarities and Differences. Disclosure (36 months) Clinical Differences/Background
Chronic Migraine versus Chronic Pain: Similarities and Differences Clinical Differences/Background David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona Disclosure (36 months)
Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
Original Article Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM) Cephalalgia 2016, Vol. 36(3) 203 215! International Headache Society 2015 Reprints
CURRICULUM VITAE Intern in Medicine, Beth Israel Hospital, Harvard Medical School, Boston, MA
Bruce D. Kohrman, M.D. 12305 SW 69 th Place Miami, Florida 33156 Telephone: (305) 903-8678 Fax: (305) 661-1672 CURRICULUM VITAE EDUCATION 1977 - B.S. Stanford University, Stanford, CA 1982 - M.D. Case
Early onset of efficacy with erenumab in patients with episodic and chronic migraine
Schwedt et al. The Journal of Headache and Pain (2018) 19:92 https://doi.org/10.1186/s10194-018-0923-6 The Journal of Headache and Pain RESEARCH ARTICLE Early onset of efficacy with erenumab in patients
NAME CTS AFFILIATION DISCLOSURE UPDATED
NAME CTS AFFILIATION DISCLOSURE UPDATED Darcy Marciniuk (Chair) and Canadian and Canadian COPD Alliance Consultant Fee, Speaker s Bureau, Advisory Committee: AstraZeneca, Boehringer-Ingelheim, Canadian
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
PROGRAM SYLLABUS. Jointly provided by Potomac Center for Medical Education and Rockpointe
PROGRAM SYLLABUS Jointly provided by Potomac Center for Medical Education and Rockpointe This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding
Organizational, or Other Financial Benefit None None None None None None. None None None None None None
Comprehensive Relationships With Industry and Other Entities AHA/ACC 2017 Update of ST-Elevation Myocardial Infarction and Non ST-Elevation Myocardial Infarction Measures Committee Jneid Hani, Chair Baylor
First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
NEXT GENERATION MIGRAINE THERAPIES. Saturday, April 6, 2019 Sheraton San Diego Hotel & Marina-Bay Tower San Diego, California
Saturday, April 6, 2019 Sheraton San Diego Hotel & Marina-Bay Tower San Diego, California Saturday, May 18, 2019 Westin Galleria Dallas Dallas, Texas Saturday, June 8, 2019 Marriott Marquis New York New
The Journal of Headache and Pain
Schwedt et al. The Journal of Headache and Pain (2018) 19:38 https://doi.org/10.1186/s10194-018-0865-z The Journal of Headache and Pain RESEARCH ARTICLE Open Access Factors associated with acute medication
SUPPLEMENTARY DATA. Telediab Study Group :
Telediab Study Group : Guillaume Charpentier, MD, Department of Diabetes, Sud-Francilien Hospital, Corbeil-Essonnes, France Centre d Études et de Recherches pour l Intensification du Traitement du Diabète
A.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
Introduction. Original Article
Original Article Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study Cephalalgia 0(0) 1 11! International
Research Submission. ISSN doi: /head Published by Wiley Periodicals, Inc. Headache 2013 American Headache Society
Headache 2013 American Headache Society ISSN 0017-8748 doi: 10.1111/head.12150 Published by Wiley Periodicals, Inc. Research Submission Sex Differences in the Prevalence, Symptoms, and Associated Features
ISSN doi: /head VC 2015 American Headache Society Published by Wiley Periodicals, Inc. Vagus Nerve Stimulation and Headache
ISSN 0017-8748 Headache doi: 10.1111/head.12721 VC 2015 American Headache Society Published by Wiley Periodicals, Inc. Supplement Article Vagus Nerve Stimulation and Headache Hsiangkuo Yuan, MD, PhD; Stephen
Faculty Disclosures. Learning Objectives
WWW.AMERICANHEADACHESOCIETY.ORG Pathophysiology Content developed by: Andrew C. Charles, MD, FAHS, Peter J. Goadsby, MD, PhD, FAHS Donna Gutterman, PharmD Faculty Disclosures ANDREW C. CHARLES, MD, FAHS
Late-Breaking Abstracts of the 2017 International Headache Congress
IHC Late Breaking Abstracts Late-Breaking Abstracts of the 2017 International Headache Congress Cephalalgia 2017, Vol. 37(1S) 319 374 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI:
Journal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
CHAPTER ONE: EXECUTIVE SUMMARY
CHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and trends Leading Competitors CHAPTER TWO: INTRODUCTION AND OVERVIEW Definition of Pain Magnitude
CJASN Editorial Team Disclosures 2018
CJASN Editorial Team Disclosures 2018 Editor in Chief Rajnish Mehrotra, MD, MBBS, FASN Organization Name: University of Washington Current Employer: University of Washington, Seattle, WA Scientific Advisor/Membership:
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
Dustin A. Heldman 1, Alberto J. Espay 2, Peter A. LeWitt 3, and Joseph P. Giuffrida 1
Dustin A. Heldman 1, Alberto J. Espay 2, Peter A. LeWitt 3, and Joseph P. Giuffrida 1 1.Great Lakes NeuroTechnologies 2.The University of Cincinnati 3.Henry Ford Health System Disclosures Dr. Heldman received
Abstract Background: Methods: Results: Conclusion:
1131 Efficacy of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Palmoplantar Psoriasis in Patients With Moderate to Severe Plaque Psoriasis in Phase 2 and Phase 3 (ESTEEM) Trials Robert Bissonnette,
Quality Indicators in Chronic Pain Management
Disclosures (2008-2013): 1. Employment: Heidelberg University 2. Advisor: Allergan, Astellas, Astra-Zeneca, Boehringer Ingelheim, Galderma, Glaxo Smith Kline, Grünenthal, Lilly, Merz, Merck-Sharpe & Dohme,
3 rd September th Biennial National Meeting on Headache 17 th - 18 th January 2019 LAZAAT RESTAURANT, COTTINGHAM, HULL
Dear Colleague, 3 rd September 2018 8 th Biennial National Meeting on Headache 17 th - 18 th January 2019 LAZAAT RESTAURANT, COTTINGHAM, HULL I have pleasure in inviting you to attend the 8 th Biennial
ESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
Canadian Stroke Best Practice Recommendations STROKE PREVENTION WRITING GROUP 2017:
Canadian Stroke Best Practice Recommendations STROKE PREVENTION WRITING GROUP 2017: NAME PROFESSIONAL ROLE LOCATION DECLARED CONFLICTS OF INTEREST Wein, Theodore Gladstone, David Côté, Robert Berlingieri,
Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn
Letter Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, openlabel study J. Rosenstock 1,2,
The Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative
Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Gregg C. Fonarow MD, Xin Zhao MS, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Mathew J. Reeves
in patients with diabetes, nephropathy and/or chronic kidney disease Summary of recommendations July 2017
Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and reninangiotensin-aldosterone system blockade in patients with diabetes, nephropathy
Supported by an unrestricted educational grant by Merck & Co.
Supported by an unrestricted educational grant by Merck & Co. TABLE OF CONTENTS Agenda & Faculty List...2 Course Description...3 Learning Objectives...3 Accreditation Statement & Credit Designation...3
A multicenter, prospective, single arm, open label, observational study of stms for migraine prevention (ESPOUSE Study)
Original Article A multicenter, prospective, single arm, open label, observational study of stms for migraine prevention (ESPOUSE Study) Cephalalgia 2018, Vol. 38(6) 1038 1048! International Headache Society
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study
Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145: 52-Week Results From the OSLER Study Michael J Koren 1, Robert P Giugliano 2, Frederick Raal 3, David
TABLE OF CONTENTS 1 Table of Contents 2 Introduction 3 Key Marketed Products
TABLE OF CONTENTS 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Epidemiology 2.2 Symptoms 2.3 Etiology 2.4 Pathophysiology 2.5 Co-morbidities and Complications 2.6 Classification
Industry Relationships and Institutional Affiliations
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher
Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative
Improving Door-to-Needle Times in Acute Ischemic Stroke: Principal Results from the Target: Stroke Initiative Gregg C. Fonarow MD, Xin Zhao MS, Eric E. Smith MD, MPH, Jeffrey L. Saver MD, Mathew J. Reeves
Global Skin Cancer Diagnosis and Therapeutics Market Research and Forecast
Report Information More information from: https://www.wiseguyreports.com/reports/3186925-global-skin-cancer-diagnosis-and-therapeuticsmarket-research Global Skin Cancer Diagnosis and Therapeutics Market
75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
Key ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
A Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
DLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES
Financial/Commercial Relationships & Conflicts of Interest DISCLOSURES All individuals able to influence or control content of any CME certified activity that will be presented were required to complete
Editors-in-Chief. Associate Editors
Editors-in-Chief C. Warren Olanow AdHoc IEC as Journal Editor The Mount Sinai School of Medicine Consultant: AbbVie, Novartis/Orion, Teva/Lundbeck, Ceregene Ownership Interest: Stock: Clintrex - (consults
University of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS NAME Financial INTERESTS Non-Financial Thomas Denberg, MD, PhD, FACP, Chair Michael J. Barry, MD, MACP Indicate Employment: Carilion
Efficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study
Efficacy and Safety of Alirocumab in Patients with Hypercholesterolemia not on Statin Therapy: the ODYSSEY CHOICE II Study Erik Stroes, 1 John Guyton, 2 Michel Farnier, 3 Norman Lepor, 4 Fernando Civeira,
Headache Cooperative of the Pacific. January 29 30, Ojai Valley Inn and Spa Ojai, California
Headache Cooperative of the Pacific The NINTH Annual HCOP Winter CONFERENCE January 29 30, 2016 Ojai Valley Inn and Spa Ojai, California Headache Cooperative of the Pacific table of contents Letter From
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC)
ToGA: Trastuzumab with Standard Chemotherapy for HER2-Positive Advanced Gastric Cancer (GC) For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians
Key ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
JEADV SHORT REPORT. Abstract
DOI: 1.1111/jdv.14738 JEADV SHORT REPORT Safety and efficacy of through 14 weeks in patients with moderate to severe psoriasis who continued on or switched from etanercept treatment: findings from the
Key ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
The new england journal of medicine original article Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine Jes Olesen, M.D., Hans-Christoph Diener, M.D.,
The best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017
Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid
Patient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
First Scientific Symposium Translational Research in Alzheimer. Paris - September 18, 2009 Collège de France
First Scientific Symposium Translational Research in Alzheimer Paris - September 18, 2009 Collège de France 8h30 Welcome coffee 9h-9h30 Opening remarks - Philippe Lagayette, President of French National
C-SSRS/KIT version includes. C-SSRS Scoring/ Administration instructions (13pgs)
This is a Sample version of the Columbia-Suicide Severity Rating Scale (C-SSRS) KIT The full version of watermark.. the C-SSRS/KIT comes without sample The full complete C-SSRS/KIT version includes C -SSRS
Characterising the premonitory stage of migraine in children: a clinic-based study of 100 patients in a specialist headache service
Karsan et al. The Journal of Headache and Pain (2016) 17:94 DOI 10.1186/s10194-016-0689-7 The Journal of Headache and Pain RESEARCH ARTICLE Characterising the premonitory stage of migraine in children:
Where do we go from Here? December 7, 2013
Where do we go from Here? December 7, 2013 Jacqueline A French MD Epilepsy Center NYU School of Medicine American Epilepsy Society Annual Meeting Disclosure I have received grant funding from The Milken
Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
June 4, Via Electronic Transmission
June 4, 2008 Via Electronic Transmission Dr. Drew Gilpin Faust President Harvard University Massachusetts Hall Cambridge, MA 02138 Dr. Peter L. Slavin President Massachusetts General Hospital (Partners
Do the Right Thing: Good Clinical Practice for Clinical Research
Do the Right Thing: Good Clinical Practice for Clinical Research Andrew A. Nierenberg, MD Director, Bipolar Clinic and Research Program, Director, Training and Education, MGH Research Institute Massachusetts
DRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
Abstracts of the 18th International Headache Congress
Volume 37, Number 1 (Supplement) September 2017 ISSN 0333-1024 (Print) ISSN 1468-2982 (Online) Abstracts of the 18th International Headache Congress International Headache Society 7 10 September 2017 Vancouver
1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
S. Holland, S.D. Silberstein, F. Freitag, et al. DOI /WNL.0b013e d0c
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults : Report of the Quality Standards Subcommittee of the American Academy of Neurology
REGISTER OF INTERESTS SIGN guideline 154: Pharmacological management of glycaemic control in people with type 2 diabetes Published: 29 November 2017
CHAIR John Petrie, Professor of Diabetic Medicine Financial Non-financial Non-personal Last updated Specific Non-Specific Specific Non- Specific Professor of Diabetic Medicine, University of Glasgow Academic.
WHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
European Headache Federation Executive Committee Meeting 12 th December, :30 17:30 Vienna, Austria MINUTES
European Headache Federation Executive Committee Meeting 12 th December, 2014 11:30 17:30 MINUTES Attending members: Dr. Mitsikostas, Dr. Osipova, Dr. Jensen, Dr. Katsarava, Dr. Martelletti, Dr. Lampl,
DECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY
AFATINIB FOLLOWED BY OSIMERTINIB IN REAL-WORLD PATIENTS WITH EGFR MUTATION-POSITIVE NSCLC: AN OBSERVATIONAL STUDY Maximilian J. Hochmair, 1 Alessandro Morabito, 2 Desiree Hao, 3 Cheng-Ta Yang, 4 Ross A.
BSGE Council Member Declaration of Interests 2017
BSGE Council Member Declaration of Interests 2017 Name Kirana Arambage BSGE Role Chair- Awards & Bursaries DoI signed on 30 Aug 2017 Dominic Byrne President 18 Aug 2017 Any office or position held in NHS
Post Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
ECMELLA. Associate Prof. Dirk Westermann, MD, PhD. Department of General and Interventional Cardiology Hamburg, Germany. Department of Medicine
ACS in Women ECMELLA Combined Impella and ECMO in Cardiogenic Shock Prof. Peter Clemmensen, MD, DMSc, FESC, FSCAI Associate Prof. Dirk Westermann, MD, PhD University Heart Center Hamburg-Eppendorf Department
Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators
Exhibitor Name Booth Number Abbott Nutrition 1030 AbbVie 301 AbbVie 907 About the Nurse 207 Academy of Medical-Surgical Nurses 144 Academy of Oncology Nurse & Patient Navigators 358 Accredo 947 Adako 276
Boston University Expert Review Meeting on the Evaluation of Novartis Access
Boston University Expert Review Meeting on the Evaluation of Novartis Access Principal Investigator: Richard Laing Co-investigators: Peter Rockers, Veronika Wirtz, Taryn Vian, Monica Onyango, Paul Ashigbie
This article is a CME/CE certified activity. To earn credit for this activity visit:
Novel Perspectives on Type 2 Diabetes: Traditional and Emerging Therapies and the Potential Role of the Kidneys This article is a CME/CE certified activity. To earn credit for this activity visit: www.medscape.org/lecture/t2dm-therapies
ESC Heart & Brain Workshop
ESC Heart & Brain Workshop Carotid Stenosis - selecting the high risk patients for intervention Alison Halliday, Professor of Vascular Surgery, University of Oxford 20 th January 2018, Prague ESC Workshop
S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
POST-SABCS Issue 1, 2013 S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013